Patent Suit Over Dermatology Drug Dismissed
“We’re very pleased,” said Dr. D. Geoffrey Shulman, chairman and chief executive of DUSA Pharmaceuticals Inc., which, along with subsidiary Sirius Laboratories Inc., was targeted by the suit.
“There was no justification in the first place,” Shulman said of the lawsuit in Georgia. “The judge recognized that...
To view the full article, register now.